Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.59 |
| ▸ | MEN1 | O00255 | 2/20 | 0.56 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.56 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.54 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.54 |
| ▸ | GRIN2B | Q13224 | 3/20 | 0.54 |
| ▸ | CHRM4 | P08173 | 3/20 | 0.51 |
| ▸ | FAAH | O00519 | 1/20 | 0.50 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13873758 | 0.94 | EPHX2 (0.56) | EPHX2MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL13873921 | 0.93 | EPHX2 (0.57) | EPHX2MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL13873555 | 0.91 | EPHX2 (0.55) | EPHX2MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL13873753 | 0.89 | ALDH1A1 (0.53) | EPHX2MEN1KMT2ASMN1; SMN2GRIN2B | |
| SCHEMBL13873556 | 0.85 | EPHX2 (0.52) | EPHX2MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL13873553 | 0.84 | ALDH1A1 (0.59) | EPHX2MEN1KMT2ASMN1; SMN2RAB9A | |
| SCHEMBL13873681 | 0.84 | MEN1 (0.51) | EPHX2MEN1KMT2AKDM4ESMN1; SMN2 | |
| SCHEMBL14413649 | 0.83 | EPHX2 (0.51) | EPHX2MEN1KMT2ASMN1; SMN2CHRM4 | |
| SCHEMBL13873680 | 0.82 | MEN1 (0.59) | EPHX2MEN1KMT2ASMN1; SMN2GRIN2B | |
| SCHEMBL17117342 | 0.80 | MEN1 (0.59) | EPHX2MEN1KMT2ASMN1; SMN2GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-04-30 | — | — | US | disclosed |
| WO-2007106705-A1 | SOLUBLE EPOXIDE HYDROLASE INHIBITORS AND METHODS OF USING SAME | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2007-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090111791-A1 | Soluble Epoxide Hydrolase Inhibitors and Methods of Using Same | EPHX1, EPHX2, NCEH1 | EPHX2 2/4885MEN1 4174/4885KMT2A 3145/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.